


A Fresh Take on Pre-Approval Inspection Data

Michael de la Torre
CEO, Redica Systems



REDICA
Systems

Is this webinar for you?



- You're asking- What's a PAI?
- You don't like data
- You came for the Starbucks gift card (hint: there is no gift card)



You work in GxP quality for Life Sciences (or consulting) and you like data!

- ✓ Compliance
- ✓ Inspection Prep
- ✓ Vendor Quality
- ✓ Training
- ✓ ...

What we will cover

1. Quick Background (2 min)
2. PAI inspection volume trends pre and post COVID
3. 483 issuance rate trends by inspection type and region
4. Differences between FDA investigators on PAI inspections
5. Top Issues cited on 483 Observations, with examples
6. Prevalence of potentially critical issues on PAI inspections
7. A short Redica commercial of how we work with Life Sciences

Who is Redica Systems?

Redica Systems - Quality and Regulatory Intelligence data analytics platform serves over 200 life sciences companies - from clinical-stage biotech to the largest global sponsors. Our customers rely on our comprehensive data sets to enable a fact-based approach to inspection preparation, vendor quality, and regulatory surveillance.

Representative customers




Unmatched data sets



- >15,000 regulatory and standards monitored daily from 200 agencies
- >1m regulatory inspections
- >25,000 Form 483s
- >17,000 Warning letters
- >16,000 EIRs and 483 Responses
- >35,000 EMA inspections and docs
- >1,500 MHRA GMP post-inspection reports
- >20,000 Health Canada inspections and docs

What you will see today: Unmatched Data



Non-FDA Data

- EMA □ 35k inspections and reports
- MHRA □ 4.5k inspection documents
- Health Canada □ 20k inspections and CRC Citations



FDA Data Comparison

- Inspections 256k □ 890k
- Inspection Documents 3k □ 59k
- Retyped 483 Observations 0 □ 110k
- Inspection Reason 0 □ 215k
- Inspector Name 0 □ 7k

Since most of our data comes from FOIA - you are going to see data and analytics that you never knew existed...

A special thank you



Jerry Chapman –
Human Dugs GMP
labeling models
and his sage
wisdom




Jason Kerr – data
wrangling,
Inspection trends
and analytics



Barb Unger –
Inspection trends
and analytics and
mentoring


Webinar Question 1

The FDA drastically cut back PAI activity during COVID. How much do you think they bounced back? (ex: 50% back to pre-covid levels, 75% or more than pre-covid)



PAI Inspection volume was dropping before COVID and fully bounced back (and then some) in North America and Europe


PAI Inspections by Region, count



* 105 PAI Inspections year-to-date as of 5/25/22


US & Canada is a much larger share of PAIs since COVID

PAI Inspections by Region, percent




Webinar Question 2

What do you think the 483 issuance rate is on PAI Inspections?




Not much change in 483 issuance rate... but is that all to the story?

483 Issuance Rate for Human Drug Inspections
(percent)



... it is a more interesting picture when you separate the data by inspection reason!


483 Issuance Rate for Human Drug Inspections by Inspection Type (percent)




... and the trends hold across all regions

483 Issuance Rate by Inspection Type, by Region (percent)


North America



Europe




Asia Pacific



Webinar Question 3

Do you have an upcoming PDUFA date? If so, when?

138 Responses



88%
N
O

Bonus Question 1


Does my specific inspector matter?

(or maybe)

How big are the differences between inspectors?

Many FDA inspectors could be your inspector, but how different could they be?

Unique FDA Inspectors active in that given year, count




Human Drugs and Biologics inspections(with HCT/P facilities removed)

My stats professor always said to “be afraid of averages”

62 inspectors with 8+ PAIs since 2017



Top PAI inspectors by 483 issuance range (2017-2022), count



Bonus Question 2

What are the top findings on PAI inspections?

(and)

Are the findings “garden variety” or potentially critical?

How did we do it? We then enriched our data with **proprietary ML models**

483 Observation/ Warning Letter Deficiency Mapping to Quality Systems

Tagging and Scoring Models

Visual Output

DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION

3/16/2020-3/20/2020

Jonathan D. Shoemaker, VP / GM

OSO BioPharmaceuticals Manufacturing, LLC (MFG)

4272 & 4200 Balloon Park Rd NE and 4401 Alexander Blvd NE
Albuquerque, NM 87109-5801

Parenteral Drug Manufacturer

DURING AN INSPECTION OF YOUR FIRM I OBSERVED:

OBSERVATION 1
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established.

For Example:

a) Operators were observed with goggles having (unprotected) holes in the top and bottom. Goggles used by operators to protect against exposed skin while working in the grade (b)(4) areas during aseptic operations having unprotected holes creates a lack of defense against a source of particles generated by, and microorganisms shed from, the face.

b) Operators reach above shoulder and hand level to gather items stored on shelving within Filling Room (b)(4) areas which may generate particles following from bench gowning. Operators were observed reaching above head height (observed 3/16/2020 Filling Line (b)(4)) to sanitize (b)(4) doors after interventions, actions which may generate particles following from bench gowning.

c) Operators were observed sanitizing gloves with sterile (b)(4) and then immediately conducting aseptic operations without pausing for a specific amount of pre-determined contact time (observed 3/16 & 3/18/2020) in

FDA 483s

Hevert Pharmaceuticals LLC USA MARCS-CMS 594842 — June 11, 2020

Product: Drugs

Recipient Name: Elizabeth Sparruth
Hevert Pharmaceuticals LLC USA
470 Saddle Rd, Suite 219
Duluth, CO 80502
United States
info@hevert.com

Issuing Office: Center for Drug Evaluation and Research (CDER)
United States

WARNING LETTER

June 11, 2020 RE 59482

Dear Ms. Sparruth:

This letter is to advise you that the United States Food and Drug Administration (FDA) has reviewed your product labeling for your injectable products "Amica", "Calmalexa comp.", "Selenium comp.", "Hepar comp.", and "Lymphobin comp.", including your products labels and your website at hevert.com. From which these products can be ordered. Based on our review these injectable products are supposed to be used under section 351 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355. Introducing or delivering these products for introduction into interstate commerce violates section 301 of the FD&C Act, 21 U.S.C. 301.

These products are especially concerning from a public health perspective because injectable drug products can pose risks of serious harm to users, these risks are less likely to occur with topical or ingested products, i.e., those applied to the skin or taken by mouth. Injectable products are delivered directly into the body, sometimes directly into the bloodstream, and therefore bypass one of the body's key defenses against toxins and microorganisms that can reach serious and life-threatening conditions. Your injectable products are further concerning because they are labeled to contain potentially toxic ingredients, such as "lax vowels" (contains skytstrine) and "plantum aciditum" (lead), thereby presenting additional risk of serious harm to patients when delivered directly into the body.

Statements on your products labels, as well as your website, that establish the intended uses of your products include, but are not limited to, the following:


- "Amica"
- "Calmalexa comp."
- "Indicated for the treatment of muscle pain and stiffness, bruising and swelling due to injuries and overexertion"
- "Calmalexa comp."
- "Indicated for the treatment of nervous disorders, such as restlessness and sleep disorders, mild depressive states, and mental exhaustion"

FDA Warning Letters

```
{
  "string": "(b)(4)\\the SIP requalification cycle failed the acceptance criteria; although the rationale for acceptance compliant as the predefined acceptance criteria were not met",
  "category": "Secondary",
  "title": "Secondary Citation",
  "regulation": "21 CFR 211.166(b)",
  "topic": "Laboratory",
  "subtopic": "Method Validation",
  "sub_subtopic": "-",
  "full_topic": "Laboratory / Method Validation / -",
  "term": "acceptance criteria",
  "source": "u_grams",
  "score": 100
},
{
  "string": "(f)\\there was no process described for the removal of oil smoke residues post smoke studies",
  "category": "Secondary",
  "title": "Secondary Citation",
  "regulation": "21 CFR 211.113(b)",
  "topic": "Production",
  "subtopic": "Sterile products",
  "sub_subtopic": "Smoke Studies",
  "full_topic": "Production / Sterile products / Smoke Studies",
  "term": "smoke studies",
  "source": "u_grams",
  "score": 100
},
{
  "string": "(g)\\The smoke study video footage would be better as single videos rather than having 3 running at the review in slow motion is recommended",
  "category": "Secondary",
  "title": "Secondary Citation",
  "regulation": "21 CFR 211.192",
  "topic": "Laboratory",
  "score": 100
}
```

Human Drugs GMP, based on the following regulatory frameworks

- 6 Quality Systems + Data Integrity
- 21 CFR 211, EUDRALEX, HC CRC Codes, ICH Q7



Redica created proprietary ML models to parse observations/ deficiencies and map them to Quality System categories

How we did it: Redica Quality System Labels for Human Drug GMP

Quality System	Packaging & Labeling	Facilities & Equipment	Materials	Laboratory	Production	Data Integrity	
<ul style="list-style-type: none"> • Agency Notification, aka GVP (BPDR, Field Alert, Recalls, Shortages) • Audit (External, Internal) • CAPA • Change Control • Complaints • Control Strategies • Deviations • Distribution • Environmental Monitoring • Equipment • Excipients • Finished Product • GMP • Inadequate • Investigations • Labeling • Management of Change • Master Production Control • Materials • Method Validation • OOS/ OOT • Process Control • Process Monitoring / Continued Process Verification • Process Validation (Blending, Sterile) • Product Contamination • Quality Assurance • Quality Control • Quality System • Risk Management • Risk Assessment • Risk Mitigation • Risk Reduction • Risk Retention • Risk Transfer • Risk Treatment • Risk Understanding • Risk Identification • Risk Evaluation • Risk Acceptance • Risk Monitoring • Risk Review • Risk Communication • Risk Reporting • Risk Assessment • Risk Mitigation • Risk Reduction • Risk Retention • Risk Transfer • Risk Treatment • Risk Understanding • Risk Identification • Risk Evaluation • Risk Acceptance • Risk Monitoring • Risk Review • Risk Communication • Risk Reporting 	<ul style="list-style-type: none"> • Drug product containers and closures (Expiration dating, Label inspection, Tamper-evident packaging) • Label and 	<ul style="list-style-type: none"> • Cleaning (Equipment, Facilities, Sterile) • Design (Equipment, Equipment construction, Facilities, Lighting, Plumbing, Sewage) 	<ul style="list-style-type: none"> • Distribution • Material Receipt and Handling (General, Quarantine of rejected components, Retesting approved) 	<ul style="list-style-type: none"> • Method Validation • OOS/ OOT • Stability (Stability Methods, Stability Program) • Systems Controls • Testing (Calibration, Equipment) 	<ul style="list-style-type: none"> • API • Batch Records • Clean Utilities • Cleaning validation or verification • Contamination Control 	<ul style="list-style-type: none"> • Process Monitoring / Continued Process Verification • Process Validation (Blending, Sterile) • Product Contamination 	<ul style="list-style-type: none"> • Accurate • Attributable (general, batch records, lab records) • Backup and Archival • Contemporaneous • Data Destruction • Data Manipulation • Data Record • Data Controls • Data Integrity
<p>Redica proprietary ML models to parse observations/ deficiencies and map them to Quality System categories</p> <p>20,000+ rules and mappings library</p>							
<ul style="list-style-type: none"> • Records and Reports 	<ul style="list-style-type: none"> • Qualified Personnel (Consultants & Contractors, Personnel, Training) • Quality Unit Inadequate (QU Missing) • Risk Management 	<ul style="list-style-type: none"> • Records and Reports 	<ul style="list-style-type: none"> • Management 	<ul style="list-style-type: none"> • Responsibilities • Process control (Calculation of yield, Charge-in of components, Equip. identification, Reprocessing, Time limitations on production) 	<ul style="list-style-type: none"> • Contamination, Personnel Monitoring, Smoke Studies, Visual Inspection) 	<ul style="list-style-type: none"> • >100 GMP Categories 	

>100 GMP Categories



How we did it: >1,500 PAI Observations analyzed (from >400 FDA 483s)

483 Observation Mapping to Quality Systems

Primary Issue(s)	Secondary Issue(s)	Primary Inferred Code(s)	Secondary Inferred Code(s)	Content
Quality System > Deviations / Investigations	Materials > Material Sampling and Testing Production > Sterile Products > Environmental Monitoring Quality System > CAPAs Production > Sterile Products > Microbiological Contamination Quality System > Deviations / Investigations Quality System > Records and Reports > Batch Release Laboratory > OOS / OOT Laboratory > Stability > Stability Program Repeat Observation	21 CFR 211.192	21 CFR 211.84(a) 21 CFR 211.42(c)(10)(iv) 21 CFR 211.192 21 CFR 211.113(b) 21 CFR 211.192 21 CFR 211.113(b) 21 CFR 211.42(c)(10)(iv) 21 CFR 211.84(a) 21 CFR 211.192 21 CFR 211.192 21 CFR 211.113(b) 21 CFR 211.42(c)(10)(iv)	<p>OBSERVATION 1</p> <p>There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.</p> <p>Specifically,</p> <p>A. Investigations into rejections of the raw material(b)(4)~ due to microbial contamination with Acinetobacter species, Klebsiella species, and Pseudomonas species have not been thorough to identify root causes and implement preventive actions to prevent the recurrence of microbial rejections of raw materials and finished drug products.</p> <p>14-CAPA-005 was initiated 08/15/2014 and documented(b)(4)~ had been rejected for Acinetobacter species once in 2010, twice in 2012, four times in 2013, and six times in</p>
Quality System > Deviations / Investigations	Production > Sterile Products > Environmental Monitoring Laboratory > Testing > Routine Testing Data Integrity > Original Data Quality System > Deviations / Investigations Quality System > Records and Reports > Procedures Materials > Material Sampling and Testing	21 CFR 211.192	21 CFR 211.42(c)(10)(iv) 21 CFR 211.165(a) 21 CFR 211.194(a) 21 CFR 211.192 21 CFR 211.100(b) 21 CFR 211.194(a) 21 CFR 211.100(b) 21 CFR 211.192 21 CFR 211.84(a)	<p>OBSERVATION 2</p> <p>Investigations of an unexplained discrepancy did not extend to other batches of the same drug product and other drug products that may have been associated with the specific failure or discrepancy.</p> <p>Specifically,</p> <p>A. Nystatin Oral Solution lots LTU1110 (3/29/2019), UV1026 (2/11/2020), UV1176</p>

SAMPLE DOWNLOADABLE OUTPUT


Quality System Labels

Inferred CFR codes from Observation text

Retyped Observation text

Sample: the top 6 issues account for ~41% of the Observational findings

Redica Human Drug GMP Labels on PAI Inspections (~400 483s analyzed),
Observation Count, %



"The Quality Unit is responsible for the review and approval of all SOPs and ensuring the appropriate SOPs are in place. If there are bad SOP or do not exist, the Quality Unit is not doing its job." Jerry Chapman

Quality Unit Inadequate!?!?

Top 10 Global Sponsor

2. There are **no written procedures for production and process controls designed** to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess....

Top 10 Global Sponsor/ Generics Firm

OBSERVATION 1

The **responsibilities and procedures applicable to the quality control unit are not fully followed.**

Specifically,

Your Quality Unit (QU) failed to fulfill its duties and responsibilities as outlined in SOP xxxxxxxx, Site Quality Unit Charter, as it did not provide adequate oversight and assurance that all operations, procedures, and systems were in conformance with appropriate regulations and standards.

OBSERVATION 3

The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.


Specifically, **your quality unit failed to draft and/or adequately implement standard operating procedures related to quality assurance**, controlled issuance of production and control records and other GMP forms, qualification and approval of contract suppliers and service providers, and good documentation practices.

Top 5 CMO

OBSERVATION 3

There are no written procedures to link the process by which escalated deviations can initiate product recall or Biological Product Deviation Reporting if discovered after release of lots. ...

But we decided to take it further – we overlaid additional “scoring” and categories



Potentially Critical Issues

Potential Cultural Issues

Potential Product Safety Issues


Failures in this area **could lead to system breakdowns**, negating the checks and balances that should be in place, possibly leading to fundamental differences with the product/processes that were registered (ex Testing into Compliance, Laboratory Controls, Quality Unit Inadequate ...)

The results, consequences, or **actions resulting from cultural attitudes** of “get lots out the door” and/or “we have always done it this way so we don’t need to follow these new rules” or “do what s/he does, follow the advice of a long-time operator who knows what s/he is doing” (ex Failure to Investigate, CAPAs, Training ...)

There should be systems in place to **detect possible safety issues with product before it goes out the door**. But if those systems are not working properly or issues come up that systems are not in place to detect, I looked at each for possible impact to the safety of the product. (ex Sewage and refuse, pest control, microbiological or other product contamination...)

Sample: Potentially critical issues

Potentially Critical Issues - Redica Human Drug GMP Labels, Observation Count, %



Top 5 CMO

2. **Laboratory controls are inadequate** to ensure quality of (b)(4) drug substance

Top 10 Sponsor

OBSERVATION 1
The **establishment of laboratory control mechanisms including any changes thereto, are not drafted by the appropriate organizational unit** and reviewed and approved by the quality control unit.

Top 10 CMO

1. Laboratory controls used to release (b)(4) drug substance **do not include scientifically sound and appropriate test procedures** that assure conformance to appropriate standards of quality and purity.


Led to GMP focused CRL

OBSERVATION 6
Laboratory controls **do not include the establishment of scientifically sound and appropriate specifications** and test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.

How prevalent are these “potentially critical” issues?


Potentially Critical Issues - Redica Human Drug GMP Labels,
% of Observations

100% = ~1,500 Observations



Potentially Critical Issues - Redica Human Drug GMP Labels,
% of Inspections

100% = ~430 Inspections




Potentially critical issues, like your CMO being cited with “Quality Unit Inadequate”, might be lurking on your next PAI...

Conclusions

- The FDA has ramped PAI inspections back to pre COVID levels for North America and Europe, but Asia is lagging way behind. There is likely a huge backlog.
- You are way more likely to get a 483 on a PAI than you think
 - ✓ PAI inspections receive 483s at a rate ~2x that of Routine inspections and almost at the same rate of For-Cause Inspections
 - ✓ PAI 483s are on the rise in all regions
- You specific FDA Investigator matters! How often they issue 483s and what they cite is heavily influenced by background and temperament – there is no “one size fits all”
- The top items cited on PAI inspections often include “the basics” of Quality Unit responsibility, Investigations, and Laboratory Controls (... and that’s *before* we get into the Sterile environment!)
- Top Sponsors and CMOs are not immune to potentially critical issues – do your research!

... and now a quick Redica
Commercial ...



REDICA
Systems

Redica Systems: Our platform

Daily Feed

The Home Dashboard features a navigation sidebar on the left with categories like 'Spotlight', 'Redica comments', and 'Applications & Approvals'. The main content area displays a 'My Feed (78)' with filters for 'All' and 'Bookmarked'. It lists regulatory updates such as 'Questions and Answers Regarding the End of the Compliance and Enforcement Policy for Certain Human Cells, Tissues, or Cellular or Tissue ...' and 'Ensuring the Rigor of Regulatory Science: CDER Conducts Laboratory and Clinical Studies to Investigate Reports of NDMA in Specific Random Products ...'.

Profiles and Reports

The profile for 'Hospira' displays a summary of regulatory data:

- Inspections: 189
- Documents in 2020: 184
- Enforcement Actions: 154
- Import Alerts: 0
- Warning Letters Issued: 12
- Warning Letter Incidence Rate: 6.35%
- 4Q3 Issued: 93
- 4Q3 Incidence Rate: 49.21%
- Product Alerts: 0

 A bar chart titled '4Q3 Observations' shows deficiencies across categories: Quality Control (100%), Production (80%), Laboratory (60%), Facilities & Equipment (40%), Data Integrity (20%), IT (10%), Packaging & Labeling (10%), and Other (10%).

Workflows

The workflow ticket (Ticket 53) details the process for reviewing and approving regulatory updates. It includes sections for 'Priority', 'Type of Service', 'Custom Type', 'Product Affected', 'Important Dates', and 'Attachments'. The 'Tasks' section shows a list of tasks with assigned users and due dates.

Intelligence Layer



Thousands of sources



Redica Systems : How we work with Life Sciences



Inspection Preparation

- ✓ Investigator profiles
- ✓ Inspection outcomes mapped to quality system
- ✓ Inspection types
- ✓ Industry Trends mapped to GxP quality system
- ✓ Peer benchmarks



Vendor Quality

- ✓ Site and Organization profiles with full inspection history
- ✓ Monitoring and alerts for inspections and enforcement
- ✓ Vendor benchmarking




Regulatory Monitoring

- ✓ Global GxP coverage
- ✓ Unique labeling
- ✓ Simple dashboard
- ✓ Integrated workflows for triage and impact assessments

Redica Reports, Visualizations and Automation

FDA Inspector Profiles

- Investigator information, including CV's in some profiles
- View at a glance key details to quickly understand the Investigator's inspection history and outcomes.
- Scan the inspection outcome through Inspection Patterns to easily understand outcomes
- Quick view of the types of Scope, Industry, and Countries inspected by the Investigator
- Spot year over year Investigator trends based on the past three years
- A breakdown of the top five cited categories of observations based on the six quality systems
- Compare the Investigator vs others in the FDA in Human Drugs/GMP built from the 483 observations in the six quality systems to spot trends
- View Top 5 cited regulations given, including the count and short descriptions



The details...

Redica has complete with compete inspectional and enforcement history and benchmarks to industry averages for all FDA inspectors going back to the year 2000

Redica Reports, Visualizations and Automation

Site & Org Profiles

1. Site information, including address and Site Registry ID's
2. Family Trees provides visibility on parent and sister companies, great to keep up with mergers and acquisitions
3. At a glance key details of each Site for a quick risk assessment
4. Quickly add Sites to your Groups to run reports and be notified of activity
5. Be in the know of how the Site is registered with the FDA through Site Tags
6. View the inspection interval days to be prepared to expect a visit from the FDA
7. Top 5 cited regulations given, including count and a short descriptions
8. Compare the Site vs others in the FDA in Human Drugs/GMP built from the 483 observations in the six quality systems
9. See the count of the available data in each tab and click to drill down on the specifics

Meridian Medical Technologies, Inc. dba Meridian Medical Tec [St. Louis / United States of America]

1945 Craig Rd, St. Louis, MO 63146, USA

Pfizer Inc family tree

Site Registry IDs: 1950222 US FDA: 29

Documents on Platform: 36

Enforcement Actions: 38

Import alerts: 0

Warning letters issued: 1

Warning letter issuance rate: 3.5%

483 issued: 20

483 issuance rate: 69.0%

Site Tags: Medical Devices, Label, Packaging, Laboratory, Manufacturer, Sterile Facility, FDP Manufacturer, Sterile, Medical Devices Manufacturer, Combination Product, Labeling, Analytical Testing, Unapproved and Misbranded Drugs, Adulterated Products

Average inspection interval in days: 237 (Avg. inspection interval), 899 (Days since last inspection)

Top 5 cited regulations:

Source	Type	Code	#
US - FDA	CFR Citation	21 CFR 820.30	9
US - FDA	CFR Citation	21 CFR 211.113	6
US - FDA	CFR Citation	21 CFR 211.100	5
US - FDA	CFR Citation	21 CFR 211.192	5
US - FDA	CFR Citation	21 CFR 211.22	4

483 Observations (Human Drugs | GMP) 52 in total

Quality Systems: 31%, Production: 26%, Laboratory: 27%, Facilities & Equipment: 21%, Data Integrity: 10%, Materials: 10%, Packaging & Labeling: 1%, Repeat Observation: 0%

Inspections (37) Enforcement Actions (38) Documents (36) Observations / Deficiencies (127) Regulatory Citations (78)

Source	Start Date	End Date	Duration(Days)	Organization	Site	Industries	Scope	Type	Reason	Outcome	Site Tags	Associated Events	Citations	Document
US - FDA	Dec 9, 2019	Dec 21, 2019	13 days	Meridian Medical Technologies	Meridian Medical Technologies, Inc. dba Meridian Medical Tec	MEDICAL DEVICES	GMP GVP	MEDICAL DEVICES COMPLIANCE	FOR CAUSE	483	MEDICAL DEVICES LABEL PACKAGING	2	12	2

The details...

Redica has >250,000 Site profiles with complete inspectional and enforcement history and benchmarks to industry averages. Redica can send email alerts when the Site is inspected or receives an Enforcement Action

Redica Reports and Automation

Example 483 Observation Report → Primary Issue = Packaging and Labeling

Filtered by: May 1, 2016 - May 1, 2022 | Human Drugs | GMP | Form 483 | Primary | Filters

Observations / Deficiencies (163)

Download


1 - 10 of 163

Inspections Date	Source	Type	Date Issued	Site	Model	Primary Issue(s)	Secondary Issue(s)	Content
Jan 13, 2022 - Jan 22, 2022 (10 days)	US - FDA	483 Observation	Jan 22, 2022	ABRYL LABORATORIES PRIVATE LIMITED [Dera Bassi / India] VILLAGE BHAGWANPUR, TEHSIL DERA BASSI, DISTRICT SHAIBZADA AJIT SINGH NAGAR, MOHALI, PUNJAB, 140507, IND	Human Drugs GMP	21 CFR 211.94 Packaging and Labeling > Drug Product Containers and Closures		OBSERVATION 3 Drug product containers and closures were not clean and sterilized and processed to... See More
Nov 9, 2021 - Jan 20, 2022 (73 days)	US - FDA	483 Observation	Jan 20, 2022	American Chinese Medicine Association, Inc [Aurora / United States of America] 2432 McKenzie Ct, Aurora, IL 60503, USA	Human Drugs GMP	21 CFR 211.130 Packaging and Labeling > Label and Packaging Controls		OBSERVATION 5 Strict control is not exercised over labeling issued for use in drug product labeling operations. Specifically, a reconciliation of labels for a packaged lot is not performed. See More
Dec 3, 2021 - Dec 13, 2021 (11 days)	US - FDA	483 Observation	Dec 13, 2021	BLA Enterprises, LLC, dba Green Mountain Pharmaceuticals [Lakewood / United States of America] 12860 W Cedar Dr #201, Lakewood, CO 80228, USA	Human Drugs GMP	21 CFR 211.125(a) Packaging and Labeling > Label and Packaging Controls > Label Issuance		OBSERVATION 5 Strict control is not exercised over labeling issued for use in drug product labeling operations. Specifically, a reconciliation of labels for a packaged lot is not performed. See More
Nov 8, 2021 - Nov 12, 2021 (5 days)	US - FDA	483 Observation	Nov 12, 2021	Gingi-Pak A Division of The Belpport Co Inc [Camarillo / United States of America] 4925 Calle Alto, Camarillo, CA	Human Drugs GMP	21 CFR 211.130(e) Packaging and Labeling > Line Clearance		OBSERVATION 5 Results of inspection of packaging and labeling facilities are not documented in th... See More
Sep 23, 2021 - Sep 29, 2021 (7 days)	US - FDA							OBSERVATION 1 Procedures describing in sufficient detail the controls employed for the issuance o... See More

The details...
Redica maps 483 observations to standard quality system categories – taking the guess work out of 483 trends!

Redica Reports, Visualizations and Automation

Organization “family trees”




The details...

Redica created proprietary organization trees of the top Pharma and MedTech companies

Thank you!

Keep in touch on Twitter
(@redicasystems) and subscribe to
our blog or book a demo on
redica.com



REDICA
Systems